Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

DA-1726

Stage Phase 1Stale

Sponsor NeuroBo Pharmaceuticals Inc

Route injection

Sources

registry, as of 2026-04-09Stale

https://clinicaltrials.gov/study/NCT06252220

First in Human Study in Subjects With Obesity, But Otherwise Healthy. Overall status RECRUITING. Phases PHASE1. Lead sponsor NeuroBo Pharmaceuticals Inc.. Enrollment 139. Conditions Obesity. This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.

ClinicalTrials.gov NCT06252220 protocol and results modules

Studies

First in Human Study in Subjects With Obesity, But Otherwise Healthy

Registry NCT06252220

Phase Phase 1

Status Recruiting

Enrollment 139

Start 2024-03-25

Primary completion 2026-11-09

Study completion 2026-11-09

Catalyst Primary completion. 2026-11-09. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part 1 - Single Ascending Dose

Comparator placebo

Population Obesity

Part 2 - Multiple Ascending Dose

Population Obesity

Part 3 - Titration

Comparator placebo

Population Obesity